APO Research
Talk to an analyst

APO RESEARCH · REPORT

Active Hemostatic Agents

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Active Hemostatic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchActive Hemostatic Agents Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Active Hemostatic Agents Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Active Hemostatic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Active Hemostatic Agents Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Active Hemostatic Agents Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Active Hemostatic Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Active Hemostatic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Active Hemostatic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Active Hemostatic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Active Hemostatic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Active Hemostatic Agents include Stryker, Johnson & Johnson Services, Pfizer Inc., Baxter International Inc., Z-Medica LLC, Warrior Tactical, LLC, Medtronic Plc., Integra Life Sciences Corporation, etc. and GELITA GA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Active Hemostatic Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Active Hemostatic Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Active Hemostatic Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Active Hemostatic Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Active Hemostatic Agents Segment by Company

Stryker

Johnson & Johnson Services

Pfizer Inc.

Baxter International Inc.

Z-Medica LLC

Warrior Tactical, LLC

Medtronic Plc.

Integra Life Sciences Corporation, etc.

GELITA GA

Ethicon Inc.

CryoLife Inc.

C.R.Bard

Biom’up

BD

B. Braun Melsungen AG

Advanced Medical Solutions Group plc

Active Hemostatic Agents

Active Hemostatic Agents Segment by Type

Combination Products

Surgical Sealants

Thrombin based hemostats

Active Hemostatic Agents Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Active Hemostatic Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Active Hemostatic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Active Hemostatic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Active Hemostatic Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Active Hemostatic Agents market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Active Hemostatic Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Active Hemostatic Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Active Hemostatic Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Active Hemostatic Agents Industry Trends Table 2. Active Hemostatic Agents Industry Drivers Table 3. Active Hemostatic Agents Industry Opportunities and Challenges Table 4. Active Hemostatic Agents Industry Restraints Table 5. Global Active Hemostatic Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Active Hemostatic Agents Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Active Hemostatic Agents Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Active Hemostatic Agents Sales Market Share by Manufacturers Table 9. Global Active Hemostatic Agents Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Active Hemostatic Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Active Hemostatic Agents Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Active Hemostatic Agents Manufacturers, Product Type & Application Table 13. Global Active Hemostatic Agents Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Active Hemostatic Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Combination Products Table 17. Major Manufacturers of Surgical Sealants Table 18. Major Manufacturers of Thrombin based hemostats Table 19. Global Active Hemostatic Agents Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Active Hemostatic Agents Sales by Type (2021-2026) & (k units) Table 21. Global Active Hemostatic Agents Sales by Type (2027-2032) & (k units) Table 22. Global Active Hemostatic Agents Sales Market Share by Type (2021-2026) Table 23. Global Active Hemostatic Agents Sales Market Share by Type (2027-2032) Table 24. Global Active Hemostatic Agents Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Active Hemostatic Agents Revenue by Type (2021-2026) & (k units) Table 26. Global Active Hemostatic Agents Revenue by Type (2027-2032) & (k units) Table 27. Global Active Hemostatic Agents Revenue Market Share by Type (2021-2026) Table 28. Global Active Hemostatic Agents Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Specialty Clinics Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Ambulatory Surgical Centers Table 32. Global Active Hemostatic Agents Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Active Hemostatic Agents Sales by Application (2021-2026) & (k units) Table 34. Global Active Hemostatic Agents Sales by Application (2027-2032) & (k units) Table 35. Global Active Hemostatic Agents Sales Market Share by Application (2021-2026) Table 36. Global Active Hemostatic Agents Sales Market Share by Application (2027-2032) Table 37. Global Active Hemostatic Agents Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Active Hemostatic Agents Revenue by Application (2021-2026) & (k units) Table 39. Global Active Hemostatic Agents Revenue by Application (2027-2032) & (k units) Table 40. Global Active Hemostatic Agents Revenue Market Share by Application (2021-2026) Table 41. Global Active Hemostatic Agents Revenue Market Share by Application (2027-2032) Table 42. Global Active Hemostatic Agents Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Active Hemostatic Agents Sales by Region (2021-2026) & (k units) Table 44. Global Active Hemostatic Agents Sales Market Share by Region (2021-2026) Table 45. Global Active Hemostatic Agents Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Active Hemostatic Agents Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Active Hemostatic Agents Sales by Country (2021-2026) & (k units) Table 49. North America Active Hemostatic Agents Sales by Country (2027-2032) & (k units) Table 50. Europe Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Active Hemostatic Agents Sales by Country (2021-2026) & (k units) Table 52. Europe Active Hemostatic Agents Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Active Hemostatic Agents Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Active Hemostatic Agents Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Active Hemostatic Agents Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Active Hemostatic Agents Sales by Country (2027-2032) & (k units) Table 59. Global Active Hemostatic Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Active Hemostatic Agents Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Active Hemostatic Agents Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Active Hemostatic Agents Revenue Market Share by Region (2021-2026) Table 63. Global Active Hemostatic Agents Revenue Market Share by Region (2027-2032) Table 64. Stryker Company Information Table 65. Stryker Business Overview Table 66. Stryker Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Stryker Active Hemostatic Agents Product Portfolio Table 68. Stryker Recent Development Table 69. Johnson & Johnson Services Company Information Table 70. Johnson & Johnson Services Business Overview Table 71. Johnson & Johnson Services Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Johnson & Johnson Services Active Hemostatic Agents Product Portfolio Table 73. Johnson & Johnson Services Recent Development Table 74. Pfizer Inc. Company Information Table 75. Pfizer Inc. Business Overview Table 76. Pfizer Inc. Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Pfizer Inc. Active Hemostatic Agents Product Portfolio Table 78. Pfizer Inc. Recent Development Table 79. Baxter International Inc. Company Information Table 80. Baxter International Inc. Business Overview Table 81. Baxter International Inc. Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Baxter International Inc. Active Hemostatic Agents Product Portfolio Table 83. Baxter International Inc. Recent Development Table 84. Z-Medica LLC Company Information Table 85. Z-Medica LLC Business Overview Table 86. Z-Medica LLC Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Z-Medica LLC Active Hemostatic Agents Product Portfolio Table 88. Z-Medica LLC Recent Development Table 89. Warrior Tactical, LLC Company Information Table 90. Warrior Tactical, LLC Business Overview Table 91. Warrior Tactical, LLC Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Warrior Tactical, LLC Active Hemostatic Agents Product Portfolio Table 93. Warrior Tactical, LLC Recent Development Table 94. Medtronic Plc. Company Information Table 95. Medtronic Plc. Business Overview Table 96. Medtronic Plc. Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Medtronic Plc. Active Hemostatic Agents Product Portfolio Table 98. Medtronic Plc. Recent Development Table 99. Integra Life Sciences Corporation, etc. Company Information Table 100. Integra Life Sciences Corporation, etc. Business Overview Table 101. Integra Life Sciences Corporation, etc. Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Integra Life Sciences Corporation, etc. Active Hemostatic Agents Product Portfolio Table 103. Integra Life Sciences Corporation, etc. Recent Development Table 104. GELITA GA Company Information Table 105. GELITA GA Business Overview Table 106. GELITA GA Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. GELITA GA Active Hemostatic Agents Product Portfolio Table 108. GELITA GA Recent Development Table 109. Ethicon Inc. Company Information Table 110. Ethicon Inc. Business Overview Table 111. Ethicon Inc. Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Ethicon Inc. Active Hemostatic Agents Product Portfolio Table 113. Ethicon Inc. Recent Development Table 114. CryoLife Inc. Company Information Table 115. CryoLife Inc. Business Overview Table 116. CryoLife Inc. Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. CryoLife Inc. Active Hemostatic Agents Product Portfolio Table 118. CryoLife Inc. Recent Development Table 119. C.R.Bard Company Information Table 120. C.R.Bard Business Overview Table 121. C.R.Bard Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. C.R.Bard Active Hemostatic Agents Product Portfolio Table 123. C.R.Bard Recent Development Table 124. Biom’up Company Information Table 125. Biom’up Business Overview Table 126. Biom’up Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Biom’up Active Hemostatic Agents Product Portfolio Table 128. Biom’up Recent Development Table 129. BD Company Information Table 130. BD Business Overview Table 131. BD Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. BD Active Hemostatic Agents Product Portfolio Table 133. BD Recent Development Table 134. B. Braun Melsungen AG Company Information Table 135. B. Braun Melsungen AG Business Overview Table 136. B. Braun Melsungen AG Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. B. Braun Melsungen AG Active Hemostatic Agents Product Portfolio Table 138. B. Braun Melsungen AG Recent Development Table 139. Advanced Medical Solutions Group plc Company Information Table 140. Advanced Medical Solutions Group plc Business Overview Table 141. Advanced Medical Solutions Group plc Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Advanced Medical Solutions Group plc Active Hemostatic Agents Product Portfolio Table 143. Advanced Medical Solutions Group plc Recent Development Table 144. Active Hemostatic Agents Company Information Table 145. Active Hemostatic Agents Business Overview Table 146. Active Hemostatic Agents Active Hemostatic Agents Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Active Hemostatic Agents Active Hemostatic Agents Product Portfolio Table 148. Active Hemostatic Agents Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Active Hemostatic Agents Distributors List Table 152. Active Hemostatic Agents Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Active Hemostatic Agents Product Image Figure 2. Global Active Hemostatic Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Active Hemostatic Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Active Hemostatic Agents Sales (2021-2032) & (k units) Figure 5. Global Active Hemostatic Agents Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Active Hemostatic Agents Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Combination Products Image Figure 9. Surgical Sealants Image Figure 10. Thrombin based hemostats Image Figure 11. Global Active Hemostatic Agents Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Active Hemostatic Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Active Hemostatic Agents Sales Market Share by Type (2021-2032) Figure 14. Global Active Hemostatic Agents Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Active Hemostatic Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Active Hemostatic Agents Revenue Market Share by Type (2021-2032) Figure 17. Specialty Clinics Image Figure 18. Hospitals Image Figure 19. Ambulatory Surgical Centers Image Figure 20. Global Active Hemostatic Agents Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Active Hemostatic Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Active Hemostatic Agents Sales Market Share by Application (2021-2032) Figure 23. Global Active Hemostatic Agents Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Active Hemostatic Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Active Hemostatic Agents Revenue Market Share by Application (2021-2032) Figure 26. North America Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Active Hemostatic Agents Sales Market Share by Country (2021-2032) Figure 28. U.S. Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Active Hemostatic Agents Sales Market Share by Country (2021-2032) Figure 33. Germany Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Active Hemostatic Agents Sales Market Share by Country (2021-2032) Figure 40. China Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Active Hemostatic Agents Sales Market Share by Country (2021-2032) Figure 48. Brazil Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Active Hemostatic Agents Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Active Hemostatic Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Active Hemostatic Agents Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Active Hemostatic Agents Revenue (2021-2032) & (US$ Million) Figure 59. North America Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Active Hemostatic Agents Revenue (2021-2032) & (US$ Million) Figure 61. Europe Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Active Hemostatic Agents Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Active Hemostatic Agents Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Active Hemostatic Agents Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Active Hemostatic Agents Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Combination Products
  • Surgical Sealants
  • Thrombin based hemostats
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
Companies covered
  • Stryker
  • Johnson & Johnson Services
  • Pfizer Inc.
  • Baxter International Inc.
  • Z-Medica LLC
  • Warrior Tactical, LLC
  • Medtronic Plc.
  • Integra Life Sciences Corporation, etc.
  • GELITA GA
  • Ethicon Inc.
  • CryoLife Inc.
  • C.R.Bard
  • Biom’up
  • BD
  • B. Braun Melsungen AG
  • Advanced Medical Solutions Group plc
  • Active Hemostatic Agents

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Active Hemostatic Agents Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Active Hemostatic Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Active Hemostatic Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Active Hemostatic Agents Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Active Hemostatic Agents Market Dynamics
  1. 2.1 Active Hemostatic Agents Industry Trends
  2. 2.2 Active Hemostatic Agents Industry Drivers
  3. 2.3 Active Hemostatic Agents Industry Opportunities and Challenges
  4. 2.4 Active Hemostatic Agents Industry Restraints
3 Active Hemostatic Agents Market by Manufacturers
  1. 3.1 Global Active Hemostatic Agents Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Active Hemostatic Agents Sales by Manufacturers (2021-2026)
  3. 3.3 Global Active Hemostatic Agents Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Active Hemostatic Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Active Hemostatic Agents Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Active Hemostatic Agents Manufacturers, Product Type & Application
  7. 3.7 Global Active Hemostatic Agents Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Active Hemostatic Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Active Hemostatic Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Active Hemostatic Agents Tier 1, Tier 2, and Tier 3
4 Active Hemostatic Agents Market by Type
  1. 4.1 Active Hemostatic Agents Type Introduction
  2. 4.1.1 Combination Products
  3. 4.1.2 Surgical Sealants
  4. 4.1.3 Thrombin based hemostats
  5. 4.2 Global Active Hemostatic Agents Sales by Type
  6. 4.2.1 Global Active Hemostatic Agents Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Active Hemostatic Agents Sales by Type (2021-2032)
  8. 4.2.3 Global Active Hemostatic Agents Sales Market Share by Type (2021-2032)
  9. 4.3 Global Active Hemostatic Agents Revenue by Type
  10. 4.3.1 Global Active Hemostatic Agents Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Active Hemostatic Agents Revenue by Type (2021-2032)
  12. 4.3.3 Global Active Hemostatic Agents Revenue Market Share by Type (2021-2032)
5 Active Hemostatic Agents Market by Application
  1. 5.1 Active Hemostatic Agents Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Ambulatory Surgical Centers
  5. 5.2 Global Active Hemostatic Agents Sales by Application
  6. 5.2.1 Global Active Hemostatic Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Active Hemostatic Agents Sales by Application (2021-2032)
  8. 5.2.3 Global Active Hemostatic Agents Sales Market Share by Application (2021-2032)
  9. 5.3 Global Active Hemostatic Agents Revenue by Application
  10. 5.3.1 Global Active Hemostatic Agents Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Active Hemostatic Agents Revenue by Application (2021-2032)
  12. 5.3.3 Global Active Hemostatic Agents Revenue Market Share by Application (2021-2032)
6 Global Active Hemostatic Agents Sales by Region
  1. 6.1 Global Active Hemostatic Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Active Hemostatic Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Active Hemostatic Agents Sales by Region (2021-2026)
  4. 6.2.2 Global Active Hemostatic Agents Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Active Hemostatic Agents Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Active Hemostatic Agents Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Active Hemostatic Agents Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Active Hemostatic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Active Hemostatic Agents Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Active Hemostatic Agents Revenue by Region
  1. 7.1 Global Active Hemostatic Agents Revenue by Region
  2. 7.1.1 Global Active Hemostatic Agents Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Active Hemostatic Agents Revenue by Region (2021-2026)
  4. 7.1.3 Global Active Hemostatic Agents Revenue by Region (2027-2032)
  5. 7.1.4 Global Active Hemostatic Agents Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Active Hemostatic Agents Revenue (2021-2032)
  8. 7.2.2 North America Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Active Hemostatic Agents Revenue (2021-2032)
  11. 7.3.2 Europe Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Active Hemostatic Agents Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Active Hemostatic Agents Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Active Hemostatic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Stryker
  2. 8.1.1 Stryker Company Information
  3. 8.1.2 Stryker Business Overview
  4. 8.1.3 Stryker Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Stryker Active Hemostatic Agents Product Portfolio
  6. 8.1.5 Stryker Recent Developments
  7. 8.2 Johnson & Johnson Services
  8. 8.2.1 Johnson & Johnson Services Company Information
  9. 8.2.2 Johnson & Johnson Services Business Overview
  10. 8.2.3 Johnson & Johnson Services Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Services Active Hemostatic Agents Product Portfolio
  12. 8.2.5 Johnson & Johnson Services Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Active Hemostatic Agents Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 Baxter International Inc.
  20. 8.4.1 Baxter International Inc. Company Information
  21. 8.4.2 Baxter International Inc. Business Overview
  22. 8.4.3 Baxter International Inc. Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Baxter International Inc. Active Hemostatic Agents Product Portfolio
  24. 8.4.5 Baxter International Inc. Recent Developments
  25. 8.5 Z-Medica LLC
  26. 8.5.1 Z-Medica LLC Company Information
  27. 8.5.2 Z-Medica LLC Business Overview
  28. 8.5.3 Z-Medica LLC Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Z-Medica LLC Active Hemostatic Agents Product Portfolio
  30. 8.5.5 Z-Medica LLC Recent Developments
  31. 8.6 Warrior Tactical, LLC
  32. 8.6.1 Warrior Tactical, LLC Company Information
  33. 8.6.2 Warrior Tactical, LLC Business Overview
  34. 8.6.3 Warrior Tactical, LLC Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Warrior Tactical, LLC Active Hemostatic Agents Product Portfolio
  36. 8.6.5 Warrior Tactical, LLC Recent Developments
  37. 8.7 Medtronic Plc.
  38. 8.7.1 Medtronic Plc. Company Information
  39. 8.7.2 Medtronic Plc. Business Overview
  40. 8.7.3 Medtronic Plc. Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Medtronic Plc. Active Hemostatic Agents Product Portfolio
  42. 8.7.5 Medtronic Plc. Recent Developments
  43. 8.8 Integra Life Sciences Corporation, etc.
  44. 8.8.1 Integra Life Sciences Corporation, etc. Company Information
  45. 8.8.2 Integra Life Sciences Corporation, etc. Business Overview
  46. 8.8.3 Integra Life Sciences Corporation, etc. Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Integra Life Sciences Corporation, etc. Active Hemostatic Agents Product Portfolio
  48. 8.8.5 Integra Life Sciences Corporation, etc. Recent Developments
  49. 8.9 GELITA GA
  50. 8.9.1 GELITA GA Company Information
  51. 8.9.2 GELITA GA Business Overview
  52. 8.9.3 GELITA GA Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GELITA GA Active Hemostatic Agents Product Portfolio
  54. 8.9.5 GELITA GA Recent Developments
  55. 8.10 Ethicon Inc.
  56. 8.10.1 Ethicon Inc. Company Information
  57. 8.10.2 Ethicon Inc. Business Overview
  58. 8.10.3 Ethicon Inc. Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ethicon Inc. Active Hemostatic Agents Product Portfolio
  60. 8.10.5 Ethicon Inc. Recent Developments
  61. 8.11 CryoLife Inc.
  62. 8.11.1 CryoLife Inc. Company Information
  63. 8.11.2 CryoLife Inc. Business Overview
  64. 8.11.3 CryoLife Inc. Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CryoLife Inc. Active Hemostatic Agents Product Portfolio
  66. 8.11.5 CryoLife Inc. Recent Developments
  67. 8.12 C.R.Bard
  68. 8.12.1 C.R.Bard Company Information
  69. 8.12.2 C.R.Bard Business Overview
  70. 8.12.3 C.R.Bard Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 C.R.Bard Active Hemostatic Agents Product Portfolio
  72. 8.12.5 C.R.Bard Recent Developments
  73. 8.13 Biom’up
  74. 8.13.1 Biom’up Company Information
  75. 8.13.2 Biom’up Business Overview
  76. 8.13.3 Biom’up Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biom’up Active Hemostatic Agents Product Portfolio
  78. 8.13.5 Biom’up Recent Developments
  79. 8.14 BD
  80. 8.14.1 BD Company Information
  81. 8.14.2 BD Business Overview
  82. 8.14.3 BD Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 BD Active Hemostatic Agents Product Portfolio
  84. 8.14.5 BD Recent Developments
  85. 8.15 B. Braun Melsungen AG
  86. 8.15.1 B. Braun Melsungen AG Company Information
  87. 8.15.2 B. Braun Melsungen AG Business Overview
  88. 8.15.3 B. Braun Melsungen AG Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 B. Braun Melsungen AG Active Hemostatic Agents Product Portfolio
  90. 8.15.5 B. Braun Melsungen AG Recent Developments
  91. 8.16 Advanced Medical Solutions Group plc
  92. 8.16.1 Advanced Medical Solutions Group plc Company Information
  93. 8.16.2 Advanced Medical Solutions Group plc Business Overview
  94. 8.16.3 Advanced Medical Solutions Group plc Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Advanced Medical Solutions Group plc Active Hemostatic Agents Product Portfolio
  96. 8.16.5 Advanced Medical Solutions Group plc Recent Developments
  97. 8.17 Active Hemostatic Agents
  98. 8.17.1 Active Hemostatic Agents Company Information
  99. 8.17.2 Active Hemostatic Agents Business Overview
  100. 8.17.3 Active Hemostatic Agents Active Hemostatic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Active Hemostatic Agents Active Hemostatic Agents Product Portfolio
  102. 8.17.5 Active Hemostatic Agents Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Active Hemostatic Agents Value Chain Analysis
  2. 9.1.1 Active Hemostatic Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Active Hemostatic Agents Production Mode & Process
  6. 9.2 Active Hemostatic Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Active Hemostatic Agents Distributors
  9. 9.2.3 Active Hemostatic Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst